MALP-2
Also known as: LP-2, Macrophage-Activating Lipopeptide-2, Macrophage‑activating lipopeptide‑2, MALP-2, MALP‑2, Mycoplasma fermentans lipopeptide 2, Pam2Cys‑SKPLG
Source MALP-2 at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
MALP-2 (macrophage‑activating lipopeptide‑2) is a diacylated lipopeptide isolated from the bacterium Mycoplasma fermentans. By binding the Toll‑like receptor 2/6 heterodimer it triggers macrophage and dendritic‑cell activation, cytokine release and nitric‑oxide production. Preclinical work shows it can boost vaccine responses, accelerate wound and bone repair, and modulate tumor and lung inflammation. Human data are limited to a small phase‑I safety study. Consequently, MALP-2 is currently a research‑only immunomodulatory compound.
Mechanism of Action
MALP-2 engages the TLR2/TLR6 heterodimer on innate immune cells, initiating MyD88‑dependent signaling that activates NF‑κB and MAPK pathways, leading to production of pro‑inflammatory cytokines and nitric oxide. Simultaneously, the lipopeptide can stimulate the Nrf2 transcription factor, inducing heme‑oxygenase‑1 (HO‑1) and other cytoprotective genes, which temper inflammation. In some contexts, MALP-2‑driven signaling interferes with p53 activity, influencing cell‑cycle and apoptotic responses. The diacylated N‑terminal palmitates are essential for receptor binding and downstream effects.
What the Research Shows
Early work (2002) identified MALP-2 as a Mycoplasma‑derived lipopeptide that activates macrophages and dendritic cells via TLR2, inducing cytokines, nitric oxide and antigen‑presenting cell maturation. A 2023 review highlighted its bidirectional modulation of monocytes, NK cells, neutrophils and lymphocytes, and its promise as a vaccine adjuvant, wound‑healing promoter, and anti‑tumor agent, based largely on animal studies. A 2020 review described MALP-2‑induced NF‑κB activation, p53 inhibition and Nrf2‑driven HO‑1 expression, linking it to both pro‑ and anti‑inflammatory outcomes. A phase‑I human trial (2008) demonstrated local tolerability of intracutaneous MALP-2 up to 1 µg per wound, with transient erythema and no systemic adverse events. Subsequent reviews (2018, 2011) discussed its role in HO‑1 induction and potential utility in sepsis or polytrauma models, but clinical efficacy data remain absent.
Reported Benefits
Preclinical evidence indicates that MALP-2 can robustly activate innate immunity, enhancing antigen presentation and cytokine production, which supports its use as a vaccine adjuvant. In animal wound‑healing models and a small human safety study, MALP-2 accelerated closure and promoted local growth‑factor release. Additional animal data suggest benefits for vascular regeneration, bone repair, tumor suppression and reduction of lung inflammation. Its ability to induce HO‑1 via Nrf2 may provide anti‑inflammatory protection in chronic disease models.
Limitations of the Evidence
The majority of data are from in‑vitro experiments or animal models; no randomized clinical trials have demonstrated therapeutic efficacy in humans. Human experience is limited to a phase‑I tolerability study that did not assess wound‑healing outcomes. The dual pro‑ and anti‑inflammatory signaling raises uncertainty about optimal dosing and safety in systemic applications. Regulatory approval has not been granted, and the compound remains classified for research use only.
Safety Considerations
In the 2008 phase‑I trial, intracutaneous MALP-2 up to 1 µg per wound caused only transient erythema and local inflammation that resolved within 48 hours, with no systemic side effects reported. Because MALP-2 activates TLR2, there is a theoretical risk of excessive cytokine release or systemic inflammation at higher doses or with systemic administration. Long‑term safety, immunogenicity and effects in vulnerable populations have not been established.
How It Is Administered
MALP-2 has been administered experimentally by intranasal, intraperitoneal, oral, subcutaneous and topical routes in preclinical studies. The only human exposure reported involved a single intracutaneous injection of a sterile aqueous solution directly into a small skin wound. Formulations used in research are typically peptide solutions prepared under sterile conditions; no commercial dosage forms exist.
Routes of Administration
Goals & Uses
- Vaccine adjuvantVaccinologyModerate
- Macrophage activation researchImmunology (Research Tool)High
- Immune activationImmunologyModerate
- anti‑tumor immunityCancer ImmunotherapyLow
- Wound healing / angiogenesisDermatology / Regenerative MedicineLow
- Antitumor immunotherapyOncologyLow
- Mucosal vaccine adjuvantImmunology / VaccinologyModerate
- Sepsis / innate immune primingInfectious DiseaseLow
Contraindications
- Active sepsis or systemic inflammatory response syndromeInfectious Disease / Critical CareHigh
- Known hypersensitivity to lipopeptidesAllergy / ImmunologyHigh
- hypersensitivity to lipopeptidesAllergyModerate
- Systemic autoimmune diseaseImmunologicalHigh
Adverse Effects
- Fever / PyrexiaSystemicCommon
- Nausea / gastrointestinal discomfortGastrointestinalUncommon
- Cytokine release syndromeImmunologicRareSystemic inflammatory response from immune activation
- HypotensionCardiovascularRareLow blood pressure
- Local injection site inflammationLocal / DermatologicCommon
- Local inflammationLocalCommonInflammatory response at or near the administration site
- FeverSystemicCommonElevated body temperature
Drug Interactions
- Immunosuppressants (e.g., corticosteroids)Moderate
- Immunosuppressants (corticosteroids, cyclosporine)Moderate
- NSAIDsLowMay increase renal risk in susceptible patients
- Other TLR agonists (e.g., LPS, CpG)Moderate
Population Constraints
- Pediatric populationsAgeRelative
- Immunocompromised patientsImmunologicRelative
- Pregnant womenReproductiveRelative
- Pregnant animalsReproductiveRelative
Regulatory Status
- European UnionInvestigationalno clinical approval
- United StatesInvestigationalused only in pre‑clinical research
- United KingdomInvestigationalresearch use only
Not approved for human therapeutic use; employed in pre‑clinical studies only.
Evidence & Sources
- Journal ArticleModerateSeya T, Matsumoto M2002-01-01T00:00:00.000000Z
- Journal ArticleModerateLiao D, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleModerateBorchsenius SN, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleModerateNiebuhr M, et al.2008-01-01T00:00:00.000000Z
- Journal ArticleModerateChernov VM, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleModerateNeunaber C, et al.2011-01-01T00:00:00.000000Z
Frequently Asked Questions
What type of molecule is MALP-2?
MALP-2 is a diacylated lipopeptide derived from the bacterium Mycoplasma fermentans. It functions as a pathogen‑associated molecular pattern that activates the Toll‑like receptor 2/6 complex on immune cells.
Has MALP-2 been tested in humans?
A small phase‑I study in 2008 injected MALP-2 into cutaneous wounds of 12 participants. The compound was locally tolerated up to 1 µg per wound, causing only brief redness and no systemic adverse events. No efficacy data were collected.
What therapeutic areas are being explored for MALP-2?
Research focuses on its use as a vaccine adjuvant, a promoter of wound and bone healing, a modulator of tumor and lung inflammation, and a potential anti‑inflammatory agent via HO‑1 induction. All evidence remains preclinical except the limited safety study.
Are there any known risks associated with MALP-2?
Because MALP-2 triggers TLR2 signaling, it can provoke strong inflammatory responses. In humans, only mild, transient local inflammation has been reported, but systemic toxicity, cytokine‑storm potential, and long‑term effects have not been evaluated.
What is MALP-2?
MALP-2 (macrophage‑activating lipopeptide‑2) is a diacylated lipopeptide isolated from the bacterium Mycoplasma fermentans. By binding the Toll‑like receptor 2/6 heterodimer it triggers macrophage and dendritic‑cell activation, cytokine release and nitric‑oxide production. Preclinical work shows it can boost vaccine responses, accelerate wound and bone repair, and modulate tumor and lung inflammation. Human data are limited to a small phase‑I safety study. Consequently, MALP-2 is currently a research‑only immunomodulatory compound.
What is MALP-2 used for?
MALP-2 is educationally associated with: Vaccine adjuvant, Macrophage activation research, Immune activation, anti‑tumor immunity, Wound healing / angiogenesis, Antitumor immunotherapy, Mucosal vaccine adjuvant, Sepsis / innate immune priming. Educational only — not medical advice.
How is MALP-2 administered?
Recorded routes of administration: Intranasal, Intraperitoneal, Intravenous, Oral, Subcutaneous, Topical.
What are the potential side effects of MALP-2?
Reported adverse effects include: Fever / Pyrexia, Nausea / gastrointestinal discomfort, Cytokine release syndrome, Hypotension, Local injection site inflammation, Local inflammation, Fever. This list is not exhaustive — consult a qualified clinician.
Who should avoid MALP-2?
Recorded contraindications: Active sepsis or systemic inflammatory response syndrome, Known hypersensitivity to lipopeptides, hypersensitivity to lipopeptides, Systemic autoimmune disease. Consult a qualified clinician before use.